Search the Newsreel

MapLight Therapeutics (MPLT) grants CDO 24K options and 6K RSUs

MapLight Therapeutics, Inc. (MPLT) reported that Chief Discovery Officer Anatol Kreitzer received equity awards on August 17, 2026. These awards include an option to purchase 24,455 shares of common stock at an exercise price of $11.245 per share, and 6,020 restricted stock units (RSUs), …

ETFs Investing in United Therapeutics Corporation Stocks

This article lists Exchange Traded Funds (ETFs) that hold stocks of United Therapeutics Corporation (UTHR), providing detailed information for each fund such as market value, weight of UTHR stock, issuer, management style, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year …

Jorey Chernett (NASDAQ: KZIA) reports multi-million ADS stake

Investor Jorey Chernett has filed an amended Schedule 13G/A, disclosing beneficial ownership of 2,339,009 American Depositary Shares (ADS) of KAZIA THERAPEUTICS LTD (NASDAQ: KZIA). This stake represents 19.6% of the company's outstanding ADS as of August 19, 2026. Chernett reports having sole voting and …

Dianthus Therapeutics director Simon Read sells $326,553 in stock By Investing.com

Dianthus Therapeutics director Simon Read sold 2,778 shares of the company's stock for $326,553, after exercising options at a lower price, all under a Rule 10b5-1 trading plan. This transaction occurred as the stock trades near its 52-week high, with InvestingPro suggesting it is …

Camp4 Therapeutics (NASDAQ: CAMP) backer sees stake diluted after new share sales

Polaris-affiliated funds and individuals have filed an amended Schedule 13D/A for Camp4 Therapeutics (NASDAQ: CAMP), indicating a diluted ownership stake. This reduction is due to Camp4's sales of additional common shares, decreasing the reporting persons' aggregate percentage ownership by over 1% since the previous …

AN2 Therapeutics (NASDAQ: ANTX) director sells 35K shares via 10b5-1 plan

AN2 Therapeutics director Robin Shane Readnour indirectly sold 35,402 shares of ANTX common stock on August 17, 2026, through pre-arranged Rule 10b5-1 trading plans. The sales occurred at a weighted average price of $6.0082 per share. Following these transactions, Readnour directly holds 9,077 ANTX …

Aardvark Therapeutics, Inc. (AARD) Under Securities Fraud Investigation – Shareholders Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz has launched a securities fraud investigation into Aardvark Therapeutics, Inc. (AARD) following significant drops in its stock price. This investigation stems from the company's voluntary pause of its Phase 3 HERO trial due to cardiac observations and …

Candel Therapeutics (NASDAQ:CADL) CTO Seshu Tyagarajan Sells 7,000 Shares of Stock

Candel Therapeutics (NASDAQ:CADL) CTO Seshu Tyagarajan sold 7,000 shares of the company's stock for $84,000, reducing his direct ownership by 8.35%. This transaction comes as CADL shares saw a 12% increase in mid-day trading to $13.50, nearing its 12-month high. Despite an EPS miss, …

Benjamin Hohl Sells 6,018 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics CFO Benjamin Hohl sold 6,018 shares of ELVN stock on August 17th for over $352,000, reducing his direct ownership by 13.07%. This transaction was part of a pre-arranged trading plan, following similar sales in July and June. Despite the insider selling, analyst …

Does Widening Losses And Higher EPS Drag Change The Bull Case For Rapport Therapeutics (RAPP)?

Rapport Therapeutics recently reported widening net losses and higher loss per share for Q2 and the half-year 2026, indicating increased cash consumption as clinical trials advance. While these financial results underscore the company's reliance on successful clinical execution and raise questions about financing risk …

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

BMO Capital analyst David Lebowitz initiated coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with an Outperform rating and a $318 price target. This article also details four other significant analyst initiations from Wednesday, covering Agomab Therapeutics NV, Biomarin Pharmaceutical Inc, KE Holdings Inc – ADR, …

Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit

Hagens Berman Sobol Shapiro LLP has announced a securities class action lawsuit against Aardvark Therapeutics, Inc. (AARD) for investors who suffered losses. The lawsuit alleges that Aardvark made misleading statements regarding the safety and efficacy of its drug ARD-101, leading to significant stock price …

Iovance Biotherapeutics Rallies as Strong Amtagvi Sales Keep Post-Earnings Momentum Alive

Rapid Synergy Malaysia 2nd-Quarter 2026 Earnings Summary Table

Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 4,730 Shares

Arcutis Biotherapeutics Director Howard Welgus sold 4,730 shares of the company's stock for $123,831.40, reducing his ownership by 11.48%. This transaction occurred under a Rule 10b5-1 trading plan. The company recently reported strong quarterly earnings of $0.11 per share and revenue of $129.86 million, …

Lexeo Therapeutics (LXEO) COO sells 1,304 shares, retains 136K stake

Lexeo Therapeutics (LXEO) Chief Operating Officer, Jose Manuel Otero, sold 1,304 shares of common stock on August 18, 2026, at a weighted average price of $4.9571 per share. This sale was conducted to cover tax obligations arising from the release of restricted stock units. …

Lexeo Therapeutics COO Jose Manuel Otero Sells Shares to Cover RSU Tax Liability

Lexeo Therapeutics COO Jose Manuel Otero sold 1,304 shares of the company's common stock on August 18, 2026, to cover tax obligations arising from the vesting of restricted stock units. The shares were sold at a weighted average price of $4.9571 per share. After …

Lexeo Therapeutics (LXEO) CFO sells shares for RSU taxes

Lexeo Therapeutics (LXEO) CFO, Louis Edward Tamayo, sold 4,117 shares of common stock on August 18, 2026, at a weighted average price of $4.91 per share. This transaction was conducted to cover tax obligations arising from the release of restricted stock units. Following the …

Lexeo Therapeutics CFO Louis Edward Tamayo Sells 4,117 Shares to Settle RSU Tax Liabilities

Lexeo Therapeutics CFO Louis Edward Tamayo sold 4,117 shares of common stock on August 18, 2026, to cover tax liabilities associated with the vesting of restricted stock units. The shares were sold at a weighted average price of $4.9071, with individual trade prices ranging …

PTC Therapeutics (NASDAQ: PTCT) CLO sells 2,813 shares under 10b5-1 plan

Mark Elliott Boulding, Executive Vice President and CLO of PTC Therapeutics (NASDAQ: PTCT), exercised stock options for 2,813 shares at $25.69 per share and subsequently sold these shares in two tranches at weighted average prices of $72.39 and $72.90 on August 17, 2026. These …

PTC Therapeutics (NASDAQ: PTCT) holder plans 50,000-share resale

A holder of PTC Therapeutics (NASDAQ: PTCT) plans to resell 50,000 common shares. The shares will be sold by Michael Schmertzler through Section Six Partners, LP, via Merrill Lynch on NASDAQ. These shares were acquired on July 4, 2012, and the sale is being …

Candel Therapeutics (CADL) CTO sells 7,000 shares via 10b5-1 plan

Candel Therapeutics (CADL) Chief Technology Officer Tyagarajan Seshu sold 7,000 shares of common stock at $12.00 per share on August 17, 2026. This transaction was conducted under a Rule 10b5-1 trading plan adopted on March 16, 2026. Following the sale, Seshu directly holds 76,865 …

Akari Therapeutics (NASDAQ: AKTX) insider updates holdings

Akari Therapeutics' Interim CFO, Farag Kameel D., reported an acquisition of 1,728 American Depositary Shares (ADS) valued at $7.52 each, totaling approximately $13,000. These shares represent restricted stock units set to vest fully on September 15, 2026. Following this transaction, Farag Kameel D. directly …

Rapid7, Tenable, CrowdStrike, Twilio, and Datadog Shares Plummet, What You Need To Know

Shares of Rapid7, Tenable, CrowdStrike, Twilio, and Datadog plummeted after a Bloomberg report revealed Anthropic's Q2 revenue topped $11.5 billion, and news broke of potential IPOs for Anthropic and OpenAI. This increased competitive pressure from AI labs, suggesting a shift in enterprise IT spending …

TherapeuticsMD(TXMD) Stock Options Chain | Quotes & News

This document is an options chain for TherapeuticsMD (TXMD) stock, providing quotes and news related to the company. It serves as a financial data resource for investors interested in TXMD.

Enliven (NASDAQ: ELVN) CFO sells 6,018 shares in 10b5-1 plan

Enliven Therapeutics, Inc.'s CFO, Benjamin Hohl, sold a total of 6,018 shares of Common Stock in two open-market transactions on August 17, 2026, under a Rule 10b5-1 trading plan. The sales were executed at weighted average prices around $58-$59 per share. A portion of …

Enliven Therapeutics (ELVN) CMO exercises options, sells stock

Enliven Therapeutics' Chief Medical Officer, Helen Louise Collins, exercised options for 5,000 shares at $2.48 per share and subsequently sold all 5,000 shares in the open market for approximately $293,000. These transactions, conducted under a Rule 10b5-1 trading plan adopted in October 2025, involved …

Arcutis (NASDAQ: ARQT) officer to sell 1,697 shares after recent August trades

Arcutis Biotherapeutics officer Patrick Burnett plans to sell 1,697 shares of common stock, valued at approximately $45,819, as detailed in a recent SEC Form 144 filing. This proposed sale follows prior transactions in August where Burnett sold significant blocks of shares. The filing also …

Travere Therapeutics (TVTX) director sells 10K shares under 10b5-1 plan

Travere Therapeutics (TVTX) director Gary A. Lyons exercised options for 10,000 shares and subsequently sold all 10,000 shares of common stock between August 17-18, 2026. The sales were conducted under a pre-arranged 10b5-1 trading plan adopted on May 18, 2026. Lyons acquired the shares …

Q2 Earnings Highlights: Graphic Packaging Holding (NYSE:GPK) Vs The Rest Of The Industrial Packaging Stocks

Q2 Earnings Highlights: Graphic Packaging Holding (NYSE:GPK) Vs The Rest Of The Industrial Packaging Stocks Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sector. Today we are looking at Graphic …

Taysha (TSHA) Results Review: Reported EPS Misses Expectations; Trading Move: The Market Price Advances 3.96% in Latest Trading - Analyst Drop Coverage

Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 10.7% - Here's What Happened

Intellia Therapeutics (NASDAQ:NTLA) saw its stock price rise by 10.7% during mid-day trading on Wednesday, though with lower-than-average trading volume. The company reported quarterly revenue of $7.66 million, missing estimates, while its adjusted loss of $0.80 per share matched expectations. Analysts have a mixed …

Trending Industry Today: Intellia Therapeutics Leads Gains In Gene Editing Stocks

Intellia Therapeutics (NTLA) is leading gains among gene-editing stocks, marking a significant upward trend within the industry. This performance highlights a positive movement for the company and potentially the broader gene-editing sector. The article focuses on NTLA's strong market performance and its implications for …

Pasithea (KTTA) Q1 2026 Earnings: EPS Clears the Reported Estimate; Session Move: The Stock Ends Down 1.21% in the Latest Reading - Low Growth Earnings

Stoke (STOK) Quarterly Figures: EPS Falls Short of Its Estimate for the Current Session; Share Move: The Stock Gains 2.64% in the Current Update - Free Cash Flow Trends

Viridian (NASDAQ: VRDN) insider to sell 14,212 shares in August 2026

An officer at Viridian Therapeutics, Inc. (VRDN), Jennifer Tousignant, plans to sell 14,212 shares of common stock valued at $348,194.00 around August 19, 2026. This sale is being made under Rule 144 and comprises shares obtained through restricted stock vesting, an ESPP purchase, and …